Jump to content

Novelos gets FDA OK for lung cancer trial

Recommended Posts

http://www.masshightech.com/displayarti ... t_ID=70457

12/05/2005 10:27 AM

Novelos Therapeutics Inc., a Newton company focused on the development of therapeutics to treat cancer and hepatitis, has received approval from the Food and Drug Administration for trials of the company’s NOV-002 into a single pivotal Phase 3 study in advanced non-small cell lung cancer, in combination with first-line chemotherapy.

Novelos will seek to finalize the Phase 3 study design under a Special Protocol Assessment during the first half of 2006.

The primary endpoint of the pivotal study will be overall survival.

Novelos was established in 1996 to commercialize two oxidized glutathione-based compounds, NOV-002 and NOV-205, for the treatment of cancer and hepatitis.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.